JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells

Human epidermal growth factor receptor 2 (HER2) targeted therapy is currently considered as the standard treatment for HER2-positive advanced gastric cancer (GC). However, unsatisfactory results of recent phase III clinical trials involving lapatinib suggested biomarkers for selection of patients. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ling, Zhu, Weiyou, Wang, Qiang, Yang, Fengming, Qian, Jing, Xu, Tongpeng, Wang, Shouyu, Zhou, Jianwei, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342123/
https://www.ncbi.nlm.nih.gov/pubmed/27708243
http://dx.doi.org/10.18632/oncotarget.12374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342123/
https://www.ncbi.nlm.nih.gov/pubmed/27708243
http://dx.doi.org/10.18632/oncotarget.12374

Ejemplares similares